Status:
COMPLETED
Phase I/IIa AdCD40L Immunogene Therapy for Malignant Melanoma and Other Solid Tumors
Lead Sponsor:
Uppsala University
Collaborating Sponsors:
Uppsala University Hospital
Conditions:
Malignant Melanoma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
In this phase I/II trial, immunostimulatory gene therapy (AdCD40L) will be investigated. In Part 1 patients with melanoma will receive AdCD40L as mono therapy. In Part 2A, patients with melanoma and p...
Detailed Description
In this phase I/II trial, immunostimulatory gene therapy (AdCD40L) will be investigated. In Part 1 patients with melanoma (n=6) will receive AdCD40L as mono therapy. In Part 2A, patients with melanoma...
Eligibility Criteria
Inclusion
- Histologically proven diagnosis of malignant solid cancer, ECOG 0-2.
- Disease progression on established treatments or patients not eligible to standard options.
- Signed informed consent must be obtained.
Exclusion
- Pregnancy.
- Life expectancy less than 3 months.
- Any significant medical or psychiatric illness that would prevent the patient from giving informed consent or from following the study procedures.
- Patients with severe systemic autoimmune disease.
- Patients that do not consent to that tissue and blood samples are stored in a biobank.
Key Trial Info
Start Date :
September 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2016
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01455259
Start Date
September 1 2011
End Date
January 1 2016
Last Update
February 17 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Uppsala University Hospital
Uppsala, Sweden, 75185